(0.24%) 5 112.45 points
(0.22%) 38 325 points
(0.25%) 15 968 points
(-1.41%) $82.67
(4.84%) $2.02
(-0.06%) $2 345.70
(-0.04%) $27.53
(3.85%) $957.60
(-0.17%) $0.933
(-0.26%) $11.00
(-0.45%) $0.797
(1.75%) $93.48
Quarter results tomorrow
(amc 2024-04-30)
Expected move: +/- 7.04%
@ $130.31
发出时间: 29 Apr 2024 @ 21:38
回报率: 0.39%
上一信号: Apr 27 - 02:22
上一信号:
回报率: 0.73 %
Live Chart Being Loaded With Signals
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases...
Stats | |
---|---|
今日成交量 | 117 345 |
平均成交量 | 835 038 |
市值 | 12.36B |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $0 ) 2024-04-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -22.59 |
ATR14 | $2.86 (2.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Wigzell Hans Lennart Rudolf | Buy | 15 000 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 3 155 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 11 745 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 100 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 15 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
35.98 |
Last 100 transactions |
Buy: 408 419 | Sell: 153 150 |
音量 相关性
Sarepta Therapeutics Inc 相关性 - 货币/商品
Sarepta Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $1.24B |
毛利润: | $1.09B (87.91 %) |
EPS: | $-5.80 |
FY | 2023 |
营收: | $1.24B |
毛利润: | $1.09B (87.91 %) |
EPS: | $-5.80 |
FY | 2022 |
营收: | $933.01M |
毛利润: | $793.02M (85.00 %) |
EPS: | $-8.03 |
FY | 2021 |
营收: | $701.89M |
毛利润: | $604.84M (86.17 %) |
EPS: | $-5.15 |
Financial Reports:
No articles found.
Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。